US Patent

US9132096 — Abuse resistant pharmaceutical compositions

Formulation · Assigned to Alkermes Pharma Ireland Ltd · Expires 2034-09-12 · 8y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an oral pharmaceutical composition with two bead populations, one containing an abused substance and the other containing a gelling agent.

USPTO Abstract

The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.

Drugs covered by this patent

Patent Metadata

Patent number
US9132096
Jurisdiction
US
Classification
Formulation
Expires
2034-09-12
Drug substance claim
No
Drug product claim
Yes
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.